ARPE-19（人视网膜色素上皮细胞）
CBP60759
询 价
ARPE19细胞全景
产品描述
产品数据库
| I. General information | |
| Synonyms: | ARPE-19 |
| Background: | ARPE-19 is a spontaneously arising retinal pigment epithelia (RPE) cell line derived in 1986 by Amy Aotaki-Keen from the normal eyes of a 19-year-old male who died from head trauma in a motor vehicle accident. The line was established in a 1:1 mixture of Dulbecco's modified Eagles medium and Ham's F12 medium with HEPES buffer containing 20% fetal bovine serum, 56 mM final concentration sodium bicarbonate and 2 mM L-glutamine and incubated at 37C in 10% CO2. The cells were subjected to selective trypsinization for the first four passages to remove superficial cells before passaging the cuboidal basal layer. By passage 5, the cultures appeared to be rapidly growing RPE cells, which would form cobblestone monolayers, which pigmented after several months in culture. |
| Species: | Homo sapiens, human |
| Tissue: | eye; retinal pigmented epithelium; retina |
| Disease: | normal |
| Gender: | male,19 years |
| Morphology: | epithelial |
| Growth Mode: | adherent |
| DNA Profile: | Amelogenin: X,YAmelogenin: X,Y CSF1PO: 11 D13S317: 11,12 D16S539: 9,11 D5S818: 13 D7S820: 9,11 THO1: 6,9.3 TPOX: 9,11 vWA: 16,19 Our Cell Line Authentication Service |
| Culture Medium: |
DMEM/F12+10%FBS ARPE-19完全培养基，# CBP60759M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | RPE-specific markers CRALBP and RPE-65 |
| Genes Expressed: | RPE-specific markers CRALBP and RPE-65 |
| Comments: | These cells form stable monolayers, which exhibit morphological and functional polarity. ARPE-19 expresses the RPE-specific markers CRALBP and RPE-65. The cells exhibit morphological polarization when plated on laminin-coated Transwell-COL filters in medium with a low serum concentration. They form tight-junctions with transepithelial resistance of monolayers reaching a maximum of 50 to 100 ohms/cm2 after 4 weeks of culture. The cells are diploid and can be carried for over 30 passages. Progeny were found to undergo an additional 48 population doublings in longevity trials performed during characterization at ATCC. For more information, please contact us (4008-750-250). |
